Brookline Cap M Boosts Earnings Estimates for Oncobiologics

Oncobiologics, Inc. (NASDAQ:OTLK) – Stock analysts at Brookline Cap M lifted their Q2 2026 earnings per share (EPS) estimates for shares of Oncobiologics in a research note issued on Monday, March 16th. Brookline Cap M analyst K. Dolliver now anticipates that the company will post earnings per share of ($0.14) for the quarter, up from their prior forecast of ($0.18). The consensus estimate for Oncobiologics’ current full-year earnings is ($2.27) per share. Brookline Cap M also issued estimates for Oncobiologics’ Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.62) EPS and FY2027 earnings at ($0.17) EPS.

Oncobiologics (NASDAQ:OTLK) last announced its quarterly earnings results on Tuesday, February 17th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). The business had revenue of ($1.21) million for the quarter, compared to analyst estimates of $3.14 million.

OTLK has been the topic of a number of other research reports. Wall Street Zen lowered shares of Oncobiologics from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Chardan Capital reiterated a “neutral” rating on shares of Oncobiologics in a research note on Wednesday, February 18th. Ascendiant Capital Markets decreased their price objective on Oncobiologics from $10.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. HC Wainwright restated a “neutral” rating on shares of Oncobiologics in a report on Wednesday, February 18th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncobiologics in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $4.50.

Oncobiologics Price Performance

Shares of NASDAQ OTLK opened at $0.34 on Thursday. The company has a 50-day moving average price of $0.45 and a 200-day moving average price of $1.07. The stock has a market capitalization of $27.93 million, a P/E ratio of -0.13 and a beta of -0.07. Oncobiologics has a 1 year low of $0.29 and a 1 year high of $3.39.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. grew its position in Oncobiologics by 865.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after purchasing an additional 21,941 shares in the last quarter. AQR Capital Management LLC increased its stake in Oncobiologics by 42.7% in the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after buying an additional 25,351 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after buying an additional 44,063 shares in the last quarter. 11.20% of the stock is owned by institutional investors.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.